We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

55 hedge funds and large institutions have $15.2M invested in Galectin Therapeutics in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more call options, than puts

Call options by funds: $759K | Put options by funds: $348K

36% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 11

0.05% more ownership

Funds ownership: 12.29% → 12.35% (+0.05%)

21% less funds holding

Funds holding: 70 → 55 (-15)

46% less capital invested

Capital invested by funds: $28.2M → $15.2M (-$13.1M)

65% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 20

Holders
55
Holders Change
-15
Holders Change %
-21.43%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
15
Reduced
11
Closed
20
Calls
$759K
Puts
$348K
Net Calls
+$411K
Net Calls Change
-$1.2M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$586K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$198K
3
Millennium Management
Millennium Management
New York
+$158K
4
SF
Synovus Financial
Georgia
+$137K
5
Morgan Stanley
Morgan Stanley
New York
+$124K

Top Sellers

Rank Fund Capital Flow
1
E
Ergoteles
New York
-$529K
2
HF
HRT Financial
New York
-$311K
3
Capstone Investment Advisors
Capstone Investment Advisors
New York
-$164K
4
PPA
Parametric Portfolio Associates
Washington
-$121K
5
CF
Centaurus Financial
California
-$88K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$48K – – –
JF
27
Jump Financial
Illinois
$48K +$66.2K +23,200 New
Charles Schwab
28
Charles Schwab
California
$37K – – –
VF
29
Virtu Financial
New York
$37K +$50.4K +17,663 New
Commonwealth Equity Services
30
Commonwealth Equity Services
Massachusetts
$34K +$14.3K +5,000 +42%
WANY
31
Wealthspire Advisors (New York)
New York
$29K – – –
Neuberger Berman Group
32
Neuberger Berman Group
New York
$28K – – –
Squarepoint
33
Squarepoint
New York
$27K -$74.3K -26,009 -66%
BSW
34
Buckingham Strategic Wealth
Missouri
$27K +$7.14K +2,500 +23%
Rockefeller Capital Management
35
Rockefeller Capital Management
New York
$26K – – –
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
$25K – – –
SKK
37
Shepherd Kaplan Krochuk
Massachusetts
$25K – – –
Goldman Sachs
38
Goldman Sachs
New York
$23K -$9.78K -3,426 -23%
Creative Planning
39
Creative Planning
Kansas
$23K +$31.5K +11,048 New
VCM
40
Vivaldi Capital Management
Illinois
$22K – – –
DAS
41
Dynamic Advisor Solutions
Arizona
$21K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$19K +$18K +6,314 +205%
CA
43
CoreCap Advisors
Michigan
$19K +$26.3K +9,195 New
Wells Fargo
44
Wells Fargo
California
$18K +$17 +6 +0.1%
Bank of America
45
Bank of America
North Carolina
$14K +$2.96K +1,036 +19%
GI
46
Gradient Investments
Minnesota
$8K – – –
Simplex Trading
47
Simplex Trading
Illinois
$8K +$12.3K +4,306 New
IA
48
IFP Advisors
Florida
$5K – – –
APA
49
American Portfolios Advisors
New York
$2.13K – – –
BCPWM
50
Bradley & Co Private Wealth Management
Florida
$2K – – –
1
2
3

GALT Hedge Fund Activity: Q4 2021 in Review

55 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2021, worth a combined $15.2M — down 46% from $28.2M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of GALT and 7 opened new positions — a net loss of 13 holders — while 11 trimmed existing stakes and 15 added.

The largest buyer was Renaissance Technologies, adding an estimated $586K. The largest seller was Ergoteles, exiting entirely with an estimated $529K sold.

  • 55 institutional investors held Galectin Therapeutics (GALT) as of Q4 2021, down from 70 in Q3 2021.
  • Funds reported $15.2M of Galectin Therapeutics stock for Q4 2021, down 46% quarter-over-quarter.
  • 7 funds opened new Galectin Therapeutics positions in Q4 2021 and 20 closed out, a net change of -13 holders.
  • The largest Galectin Therapeutics buyer in Q4 2021 was Renaissance Technologies, an estimated $586K added.
  • The largest Galectin Therapeutics seller in Q4 2021 was Ergoteles, an estimated $529K sold.

Based on aggregated 13F filings for Q4 2021.